Elamipretide A Novel Therapeutic Approach

Preclinical and clinical studies conducted by laboratories and clinicians worldwide have supported the development of elamipretide.6, 8, 39, 42 Stealth BioTherapeutics is focused on the opportunity to treat both rare mitochondrial diseases and diseases in major therapeutic categories involving mitochondrial dysfunction. Inherited, rare mitochondrial diseases are characterized by known genetic defects, and there are more than 250 of these genetic mutations that can cause mitochondrial disease. Common diseases such as neurodegenerative diseases, renal disease and age-related macular degeneration are also well-understood to involve mitochondrial dysfunction.4, 11, 37

Our investigational compound, elamipretide, is formulated for systemic (subcutaneous injection and intravenous infusion) and topical ophthalmic delivery. Elamipretide is uniquely able to target the inner mitochondrial membrane, restoring electron transport to improve cellular energy production and reduce oxidative stress created by the over-production of ROS.8


Clinical Milestones

The clinical development for elamipretide has been structured to assess whether there is evidence of potentially favorable clinical effects across multiple therapeutic areas and to advance toward later-stage trials and registration in both rare and common diseases.

Mitochondrial Platform

Clinical Studies and Pipeline Development

cp-20171107 Trial Indication Phase ELAMIPRETIDE Primary Mitochondrial Diseases MMPOWER-3 Mitochondrial Myopathy Phase III MMPOWER-2 Mitochondrial Myopathy Phase II RePOWER Mitochondrial Myopathy Prospective/Non-Interventional TAZPOWER Barth Syndrome Phase II / III ReSIGHT Leber’s Hereditary Optic Neuropathy Phase II Diseases Associated with Aging PROGRESS-HF Heart Failure (HFrEF) Phase II RESTORE-HF Heart Failure (HFpEF) Phase II IDDEA-HF Heart Failure (Acute) Phase II ReVEAL Fuchs’ Corneal Dystrophy Phase I / II ReCLAIM Dry Age-Related Macular Degeneration Phase I Neurodegenerative Disease CHALLENGE-HD Huntington's Disease Phase I / II Rare Disease Indication Common Disease Indication SBT-20 Ocular Skeletal Muscle Cardiorenal Neurological Ocular Cardiorenal